Harvard Bioscience INC 8-K filings

Harvard Bioscience announced its third quarter 2024 financial results, revealing a decrease in revenue and a net loss, while also highlighting cost-saving initiatives and the completion of a key system migration.

Harvard Bioscience announced lower than expected second quarter revenues and has reduced its full year revenue outlook due to a delayed market recovery.

Harvard Bioscience held its 2024 Annual Meeting of Stockholders, where a director was elected, the appointment of an auditor was ratified, and executive compensation was approved in a non-binding advisory vote.

Harvard Bioscience announced its first quarter 2024 financial results, showing a revenue decrease due to market headwinds, particularly in APAC, but maintained a strong gross margin and initiated cost reduction efforts.

Harvard Bioscience has amended its credit agreement to allow for increased EBITDA adjustments related to an employee retention credit and an escheatment audit.

Harvard Bioscience's Compensation Committee has approved a 2024 annual cash incentive plan for its CEO and CFO, linking bonuses to the achievement of corporate financial objectives.

Harvard Bioscience announced its Q4 and full-year 2023 financial results, showing a slight revenue decrease in Q4 but significant improvements in gross margin and debt reduction for the full year.